<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733483</url>
  </required_header>
  <id_info>
    <org_study_id>18-0015</org_study_id>
    <secondary_id>K23AR070275</secondary_id>
    <nct_id>NCT03733483</nct_id>
  </id_info>
  <brief_title>Sleep Disruption Induced Impairments in Bone Formation</brief_title>
  <acronym>SIIB</acronym>
  <official_title>Mechanisms for Sleep/Circadian Disruption-Induced Impairments in Bone Formation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a small intervention study with healthy males aged 20-65 years old who habitually&#xD;
      sleep 7-9 hours/night.This study investigates if and how sleep restriction, independent of&#xD;
      circadian misalignment (e.g. shift work, jet lag), induces a decrease in the bone formation&#xD;
      marker Procollagen I Intact N-Terminal Propeptide (PINP). The specific aim is to evaluate the&#xD;
      mechanistic underpinnings for the relationship between sleep restriction and suppression of&#xD;
      bone formation. The study will enroll 12 healthy male participants and have a two-week&#xD;
      intervention after enrollment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Actual">March 16, 2020</completion_date>
  <primary_completion_date type="Actual">March 16, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects are their own controls, with baseline measurements serving as the control values prior to intervention.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Pro-collagen 1 Intact N-terminal Propeptide (P1NP)</measure>
    <time_frame>24 hour serum draw before and after 6 night sleep restriction. Pre measures taken on night 1 through day 2. Post measures taken on night 7 through day 8. A fasting blood sample will be taken each morning of the inpatient stay.</time_frame>
    <description>A marker of bone formation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum C-telopeptide of Type 1 Collagen (CTX)</measure>
    <time_frame>24 hour serum draw before and after 6 night sleep restriction. Pre measures taken on night 1 through day 2. Post measures taken on night 7 through day 8. A fasting blood sample will be taken each morning of the inpatient stay.</time_frame>
    <description>A marker of bone resorption</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sleep Deprivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sleep Deprivation</intervention_name>
    <description>Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.</description>
    <arm_group_label>Sleep Deprivation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        o Adult men aged 20-65 years old who habitually sleep 7-9 hours/night.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Regularly go to sleep after midnight;&#xD;
&#xD;
          -  Shift work 1 year prior to study;&#xD;
&#xD;
          -  Travel &gt;1 time zone 4 weeks prior to study or need to travel during study;&#xD;
&#xD;
          -  More than moderate activity level (&gt;3 days of exercise per week &gt;30 min of exercise&#xD;
             per session);&#xD;
&#xD;
          -  Current smokers (or within the previous year of study);&#xD;
&#xD;
          -  Positive drug test at screening or laboratory admission;&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2;&#xD;
&#xD;
          -  Individuals who are concurrently participating in another research protocol that would&#xD;
             influence their safe participation in this study. For example, participants involved&#xD;
             in a study that requires blood draws or ingestion of experimental medication as this&#xD;
             would increase the risk of participation in our study and/or compromise study results.&#xD;
&#xD;
          -  Any clinically significant unstable medical or surgical condition within the last year&#xD;
             (treated or untreated), including history of a clinically significant abnormality of&#xD;
             the neurological system (including cognitive disorders or significant head injury) or&#xD;
             any history of seizure (including febrile seizure-sleep loss has been used clinically&#xD;
             to induce seizures in patients with epilepsy). Given the wide range of illnesses that&#xD;
             are encountered in medical practice, it would not be possible to provide a&#xD;
             comprehensive list of each and every disease that could serve as grounds for exclusion&#xD;
             for the subject. However, the following is a list of illness categories that would&#xD;
             certainly be grounds for exclusion: Connective Tissue and Joint Disorders;&#xD;
             Neurologic/cognitive Disorders; Musculoskeletal Disorders; Immune Disorders;&#xD;
             Chronobiologic Disorders; Cardiovascular Disorders; Respiratory Disorders; Kidney&#xD;
             Disorders; Infectious Diseases; Hematopoietic Disorders; Neoplastic Diseases; and&#xD;
             Endocrine and Metabolic Diseases.&#xD;
&#xD;
          -  Self-reported or newly diagnosed medical condition that is still being investigated or&#xD;
             is not under good control, including those identified on screening labs such as:&#xD;
&#xD;
               -  Out-of-range values measured on a fasting blood sample: glucose &gt; 100 mg/dl,&#xD;
                  thyroid stimulating hormone &lt;0.5 or &gt;5.0 uU/ml, abnormal alkaline phosphatase &lt;39&#xD;
                  or &gt;117 U/l, creatinine, or hemoglobin &lt;14.5 g/dl men&#xD;
&#xD;
          -  Any clinically significant psychiatric condition, as defined by DSM-V. Individuals&#xD;
             with a history of most psychiatric illnesses or psychiatric disorders will be&#xD;
             excluded, such as but not limited to depression, anxiety, alcoholism, drug dependency,&#xD;
             schizophrenic disorders, and personality disorders (performed by medical history and&#xD;
             physician interview). However, a personal history of limited prior counseling,&#xD;
             psychotherapy (e.g., for adjustment reactions) will NOT be exclusionary. Evaluation of&#xD;
             Psychiatric/Psychological Suitability:&#xD;
&#xD;
               -  Subjects must demonstrate a full understanding of the requirements and demands of&#xD;
                  the study.&#xD;
&#xD;
               -  Each subject will complete psychological screening questionnaires. Exclusionary:&#xD;
                  Center for Epidemiological Studies Depression (CES-D) ≥ 16;. Subject responses to&#xD;
                  the CES-D are reviewed immediately and appropriate referrals are made if&#xD;
                  necessary.&#xD;
&#xD;
               -  Individuals who are unaware of specific psychiatric diagnoses who have a history&#xD;
                  of having been treated with antidepressants, neuroleptic medications or major&#xD;
                  tranquilizers will be excluded from study.&#xD;
&#xD;
               -  Use of anti-depressants or any like therapeutics prescribed by a physician is&#xD;
                  exclusionary&#xD;
&#xD;
          -  Individuals with any clinically significant sleep disorder; Diagnosis or symptoms of&#xD;
             sleep disorders (history of significant parasomnia as an adult [night terrors,&#xD;
             frequent sleep walking], insomnia, including but not limited to hypersomnias such as&#xD;
             apnea, periodic limb movements, narcolepsy). Sleep disorders will be screened by&#xD;
             self-report and physician interview including use of validated sleep questionnaires&#xD;
             (PSQI, Epworth sleepiness scale, and Berlin sleep questionnaire for sleep apnea).&#xD;
&#xD;
          -  Individuals on medications known to affect bone turnover (e.g. glucocorticoids,&#xD;
             osteoporosis medications);&#xD;
&#xD;
          -  Use of medications/supplements/drugs that impact sleep or bone metabolism (such as but&#xD;
             not limited to sleep medications, marijuana etc.) within one month (participants can&#xD;
             be studied at a later date).&#xD;
&#xD;
          -  Dwelling below Denver altitude (1,600 m) 6 months prior to testing;&#xD;
&#xD;
          -  Greater than moderate caffeine (&gt;500 mg/day) or alcohol use (&gt;14 standard drinks/week&#xD;
             or &gt;5 drinks in one sitting);&#xD;
&#xD;
          -  Subjects with a history of heparin-induced thrombocytopenia (HIT) or an allergy to&#xD;
             heparin;&#xD;
&#xD;
          -  Inability to travel to the CU-AMC campus for study visits.&#xD;
&#xD;
          -  Individuals with restrictive diets (e.g., vegan)&#xD;
&#xD;
          -  Individuals with 25OHD &lt; 20 ng/mL;&#xD;
&#xD;
          -  Individuals with eGFR &lt; 60 mL/min/1.73m2 as this is known to affect CTX measurements;&#xD;
&#xD;
          -  T-score ≤ -2.5 (men ≥50 years old) or Z-score &lt; -2.0 (men &lt;50 years old) for bone&#xD;
             mineral density (BMD) at the L-spine, femoral neck, or total hip on baseline DXA as&#xD;
             compared to the DXA machine's normative database;&#xD;
&#xD;
          -  Symptoms of active illness (e.g., fever); note that subject can be studied at a later&#xD;
             date.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Swanson, MD, MCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical &amp; Translational Research Centers (CTRC) UCHealth</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Swanson CM, Shea SA, Wolfe P, Cain SW, Munch M, Vujovic N, Czeisler CA, Buxton OM, Orwoll ES. Bone Turnover Markers After Sleep Restriction and Circadian Disruption: A Mechanism for Sleep-Related Bone Loss in Humans. J Clin Endocrinol Metab. 2017 Oct 1;102(10):3722-3730. doi: 10.1210/jc.2017-01147.</citation>
    <PMID>28973223</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <results_first_submitted>June 18, 2021</results_first_submitted>
  <results_first_submitted_qc>June 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2021</results_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone</keyword>
  <keyword>Sleep Restriction</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03733483/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sleep Deprivation</title>
          <description>Sleep Deprivation: Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sleep Deprivation</title>
          <description>Sleep Deprivation: Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Pro-collagen 1 Intact N-terminal Propeptide (P1NP)</title>
        <description>A marker of bone formation</description>
        <time_frame>24 hour serum draw before and after 6 night sleep restriction. Pre measures taken on night 1 through day 2. Post measures taken on night 7 through day 8. A fasting blood sample will be taken each morning of the inpatient stay.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sleep Deprivation</title>
            <description>Sleep Deprivation: Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Pro-collagen 1 Intact N-terminal Propeptide (P1NP)</title>
          <description>A marker of bone formation</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Maximum likelihood estimates in a repeated measures model were used to assess the effect of insufficient sleep on P1NP levels. Change in P1NP in response to insufficient sleep was assessed using values measured every two hours on two, 24-h profiles obtained at baseline and on night 6 of sleep restriction. Circadian rhythmicity was included in the repeated-measures model as diurnal variation has been documented in prior studies. Data are presented as estimate ± standard error of the estimate.</non_inferiority_desc>
            <p_value>0.53</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum C-telopeptide of Type 1 Collagen (CTX)</title>
        <description>A marker of bone resorption</description>
        <time_frame>24 hour serum draw before and after 6 night sleep restriction. Pre measures taken on night 1 through day 2. Post measures taken on night 7 through day 8. A fasting blood sample will be taken each morning of the inpatient stay.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sleep Deprivation</title>
            <description>Sleep Deprivation: Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum C-telopeptide of Type 1 Collagen (CTX)</title>
          <description>A marker of bone resorption</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.197" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.459" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Maximum likelihood estimates in a repeated measures model were used to assess the effect of insufficient sleep on CTX levels. Change in CTX in response to insufficient sleep was assessed using values measured every two hours on two, 24-h profiles obtained at baseline and on night 6 of sleep restriction. Circadian rhythmicity was included in the repeated-measures model as diurnal variation has been documented in prior studies. Data are presented as estimate ± standard error of the estimate.</non_inferiority_desc>
            <p_value>0.10</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected while subjects were enrolled in the study. This included during their screening visit and during the 16 -37 days they were enrolled in the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sleep Deprivation</title>
          <description>Sleep Deprivation: Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eyes</sub_title>
                <description>One participant experienced eye discomfort during the inpatient sleep restriction portion of the study. This was resolved with saline eye drops</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Irritation</sub_title>
                <description>One participant experienced skin irritation due to the tape used with our IV catheter. Skin irritation resolved within 7 days.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>1) A protocol deviation resulted in slightly longer sleep duration on one night in one participant. Results were unchanged when data were re-analyzed without data from that participant. 2) This data was from a small cohort of young, healthy, physically active men. 3) Activity restrictions imposed during sleep restriction may not accurately reflect activity during real-life sleep restriction. 4) Study diets provided may not accurately replicate real-life changes in diet due to sleep restriction.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christine Swanson, MD, MCR, Assistant Professor</name_or_title>
      <organization>University of Colorado, Anschutz Medical Campus</organization>
      <phone>(303)724-0073</phone>
      <email>christine.swanson@cuanschutz.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

